Trial Profile
A Randomised, Double Blind, Placebo Controlled, Parallel Group Efficacy and Safety Study of Oral Administration of Empagliflozin Twice Daily Versus Once Daily in Two Different Daily Doses Over 16 Weeks as add-on Therapy to a Twice Daily Dosing Regimen of Metformin in Patients With Type 2 Diabetes Mellitus and Insufficient Glycaemic Control
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 11 Oct 2021
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Metformin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim; Boehringer Ingelheim Pharmaceuticals
- 19 Sep 2014 Primary endpoint has been met (Change from baseline in HbA1c after 16 weeks of treatment), according to the results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 19 Sep 2014 Results presented at the 50th Annual Meeting of the European Association for the Study of Diabetes.
- 10 Dec 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.